Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

University of Manitoba: Clinical Trials & FDA Approval Profile

University of Manitoba (Global / Institutional) sponsors 24 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 12 active protocols (8 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)8.3%
Median Closed Enrollment vs National (145 pts)45 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for University of Manitoba
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)24
Active Pipeline (Recruiting Now)12 (8)
Completed vs Stopped Early7 / 2 (8.3%)
Median Closed Actual Enrollment45 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With University of Manitoba
Hospital Research SiteLocationShared Protocols
St. Michael's HospitalToronto, Ontario3
CancerCare ManitobaWinnipeg, Manitoba2
University of Chicago MedicineChicago, IL2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by University of Manitoba
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05848713AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired PneumoniaPhase IIIRECRUITING
NCT03378466Heparin Anticoagulation in Septic ShockPhase IITERMINATED

Explore interactive annual charts and M&A subsidiary rollups in the University of Manitoba Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI